

What Matters Most for Long-Acting Antiretroviral Therapy? A Discrete Choice Experiment

Presented by: Rebecca Fisk-Hoffman, MPH

Continuum 2024 · June 9-11, 2024 · Puerto Rico



Funding

 Supported by the National Institute on Alcohol Abuse and Alcoholism (F31AA030518, U24AA022002), the National Institute of Allergy and Infectious Disease (R01AI172875), and Merck's Investigator-Initiated Program




Background

- Alternative to daily pills needed and many options in development
 - Unknown what PWH may prefer in a treatment
 - Increases the likelihood of uptake
- More work on PrEP preferences and limited studies in PWH
 - More effective, less often, cost, side effects, type
 - Focus on MSM or outside US
 - PWH studies have geographic differences
- Aim: Assess preferences for long-acting ART characteristics using a discrete choice experiment




Methods: The Florida Cohort

- NIAAA-funded longitudinal study to identify barriers to HIV care continuum steps
- Enrolled adult PWH from clinics and case management agencies
 - October 2020-November 2023
- Baseline battery included multiple modules
 - 6- and 12-month follow-ups at some sites
- Written informed consent before participation



Methods

- Cross-sectional data from the Florida Cohort
 - February 2023-November 2023
- 12 Best-worst scaling DCE tasks
- Attributes and levels selected based on literature and earlier quantitative and qualitative work
- Hierarchical Bayes model
 - Exploratory Latent Class Analysis
- Sawtooth Software



(1 of 12) Which of the following HIV treatments do yout think is the best option? Which is the worst option?

#CONTINUUM2024





4


Methods

Attribute	Level	Attribute	Level
Туре	Implant	Side Effects	Mild diarrhea
	Shot		Mild fatigue
	Pill		Mild pain
	Patch		Moderate diarrhea
Frequency	Weekly		Moderate fatigue
	Monthly		Moderate pain
	Bi-monthly	Convenience	Home
	Quarterly		Pharmacy
	Semi-annually		HIV doctor's office
	Annually		Mobile clinic
Long-term Effects	No risk-liver	Effectiveness	Same as pills
	No risk-kidney		Better than pills
	No risk- weight gain	Opt-Out	Current regimen
	1% risk-liver		
	1% risk-kidney		
	1% risk-weight gain		




- Study sample
 - 208 participants completed
 - 59% aged 50+
 - 48% non-Hispanic Black, 12% Hispanic
 - 91% on oral ART (89% adherent)


































- Two classes:
- "Type Driven"
 - Prefer current treatment
 - Strong preference for pills
- "Frequency Driven"
 - Prefer alternatives
 - Strong preference for longer lasting
 - Still prefer pills





Conclusions

- Type of treatment and frequency most important attributes
 - Pills
 - Annual administration
- Defined the two identified classes
 - Minority will likely stay on oral ART
- Having a menu of options may help PWH find ART that best fits their lives



Acknowledgments

- Co-authors
 - Yiyang Liu
 - Charurut Somboonwit
 - Maya Widmeyer
 - Lori Bilello
 - Mattia Prosperi
 - Ramzi Salloum
 - Robert Cook

- Florida Cohort
 - Coordinators
 - Research Assistants
 - Participants